Two Psilocybe mushroom species from the Venezuelan Andes, P. montana and P. pseudobullacea, were analyzed for the hallucinogens psilocybin and psilocin using thin-layer chromatography and UV spectroscopy. Psilocybin and psilocin were detected in P. pseudobullacea, while P. montana contained neither compound.
Between 2009 and 2015, 56 samples of the potent hallucinogen 25I-NBOMe were identified among 21,198 drug samples submitted to a Spanish harm-reduction service. Most samples (42.8%) were sold as LSD, while only 21.4% were sold as 25I-NBOMe itself; others were misrepresented as related substances or even gummy bears. All 25I-NBOMe samples appeared after 2012, with a peak in 2013. The substance has high affinity for serotonin 5HT2a receptors and has been linked to toxicity. The authors call for more research and for physicians to be aware of novel psychoactive substances and their clinical differences.